GLP1R and type 1 diabetes mellitus: No T1DM patient was under sulfonylureas, glucagon-like peptide-1 receptor agonists (GLP1-ra) or sodium-glucose co-transporter-2 inhibitors (SGLT2i), which were prescribed in a minority of LADA patients.